Видео с ютуба Adaura

ADAURA Trial: Tagrisso & Resectable EGFR+ - Leading Developments & Current Questions in Lung Cancer

ADAURA Trial; Early Stage Non–Small Cell Lung Cancer

The ADAURA Trial: Flaws and Results - Leading Developments & Current Questions in Lung Cancer

Discussion on the ADAURA study

ADAURA OS - Control arm participants who progressed got poor medical care - Unethical pharma trial

ADAURA: Osimertinib as Adjuvant Therapy in Stage III EGFR+ NSCLC

ASCO 2023 Highlights on adjuvant osimertinib in resected EGFR mutated NSCLC: The ADAURA trial

Updates from ADAURA: continued DFS benefit with osimertinib vs. placebo

Adjuvant osimertinib in resected EGFRm NSCLC: the OS data from the ADAURA trial

ADAURA Trial: MRD Analysis of Adjuvant Osimertinib in Resected EGFR-Mutated NSCLC – ASCO 2024

Overall-survival analysis of ADAURA: osimertinib in resected EGFRm stage IB-IIIA NSCLC

ADAURA: osimertinib adjuvant therapy in EGFR mutated NSCLC

ADAURA Phase III Trial Data: Practice Changing?

The Oncology Brothers Discuss ADAURA Trial Findings

ADAURA clinical trial update

Key Points from the Adaura Trial: Osimertinib - Targeted Therapies in Lung Cancer 2023

Reflections on the ADAURA study

Analysis of patients’ side effects and quality of life in the ADAURA study

The Adaura Trial: The Effect on EGFR+ Treatment

ADAURA Trial: Osimertinib for Early Stage EGFR+ NSCLC - 2022 Program: Targeted Therapies Forum